PSD502 meets Phase III endpoints

Sciele Pharma Inc. and Plethora Solutions Holdings plc (LSE:PLE) said PSD502 met the four co-primary endpoints in a Phase III trial to treat premature ejaculation (PE). Sciele said final data will be announced by year end, and regulatory applications will be submitted in the U.S. and EU in 1H10. ...